MX2007001292A - Metodo para modular la expresion genica al alterar el contendido de cpg. - Google Patents

Metodo para modular la expresion genica al alterar el contendido de cpg.

Info

Publication number
MX2007001292A
MX2007001292A MX2007001292A MX2007001292A MX2007001292A MX 2007001292 A MX2007001292 A MX 2007001292A MX 2007001292 A MX2007001292 A MX 2007001292A MX 2007001292 A MX2007001292 A MX 2007001292A MX 2007001292 A MX2007001292 A MX 2007001292A
Authority
MX
Mexico
Prior art keywords
modifying
gene expression
modulating gene
cpg content
relates
Prior art date
Application number
MX2007001292A
Other languages
English (en)
Inventor
Frank Notka
Marcus Graf
Doris Leikam
Ralf Wagner
David Raab
Original Assignee
Geneart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35839637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2007001292(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE200410037652 external-priority patent/DE102004037652B4/de
Priority claimed from DE102004037611A external-priority patent/DE102004037611B4/de
Application filed by Geneart Ag filed Critical Geneart Ag
Publication of MX2007001292A publication Critical patent/MX2007001292A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/46—Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Electrotherapy Devices (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Control Of Electric Motors In General (AREA)

Abstract

La invencion se refiere a modificaciones de acido nucleico para una modulacion de expresion dirigida por la insercion o remocion dirigida de dinucleotidos de CpG. La invencio tambien se refiere a acidos nucleidos modificados y vectores de expresion modificados.
MX2007001292A 2004-08-03 2005-08-03 Metodo para modular la expresion genica al alterar el contendido de cpg. MX2007001292A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE200410037652 DE102004037652B4 (de) 2004-08-03 2004-08-03 Verfahren zur Modulation der Genexpression durch Änderung des CpG Gehalts
DE102004037611A DE102004037611B4 (de) 2004-08-03 2004-08-03 Induzierbare Genexpression
PCT/EP2005/008423 WO2006015789A2 (de) 2004-08-03 2005-08-03 Verfahren zur modulation der genexpression durch änderung des cpg gehalts

Publications (1)

Publication Number Publication Date
MX2007001292A true MX2007001292A (es) 2007-07-04

Family

ID=35839637

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007001292A MX2007001292A (es) 2004-08-03 2005-08-03 Metodo para modular la expresion genica al alterar el contendido de cpg.

Country Status (14)

Country Link
US (4) US8859275B2 (es)
EP (1) EP1776460B8 (es)
JP (1) JP4550115B2 (es)
KR (1) KR101222628B1 (es)
AT (1) ATE453716T1 (es)
AU (1) AU2005270430B2 (es)
BR (1) BRPI0513081A (es)
CA (1) CA2575490A1 (es)
DE (1) DE502005008794D1 (es)
DK (1) DK1776460T3 (es)
HK (1) HK1100089A1 (es)
IL (1) IL180786A (es)
MX (1) MX2007001292A (es)
WO (1) WO2006015789A2 (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1776460T3 (da) 2004-08-03 2010-04-12 Geneart Ag Fremgangsmåde til modulering af genekspression ved ændring af CpG-indholdet
US9303080B2 (en) 2006-01-13 2016-04-05 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells
GB0606190D0 (en) 2006-03-28 2006-05-10 Isis Innovation Construct
WO2008069663A1 (en) 2006-12-07 2008-06-12 Publiekrechtelijke Rechtspersoon Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum Use of a varicellovirus tap-inhibitor for the induction of tumor- or virus-specific immunity against teipp
CN101861168B (zh) 2007-05-07 2014-07-02 米迪缪尼有限公司 抗-icos抗体及其在治疗肿瘤、移植和自身免疫病中的应用
EP2019134A1 (en) * 2007-07-26 2009-01-28 Vision 7 GmbH Gene therapy of chronic granulomatous disease
BRPI0814459B1 (pt) 2007-07-26 2023-01-24 Uniqure Ip B.V Método para produzir um vírion parvoviral recombinante em uma célula de inseto, e, construção de ácido nucleico
JP5728389B2 (ja) 2009-01-30 2015-06-03 ユニキュアー アイピー ビー．ブイ． アラニン−グリオキシル酸アミノトランスフェラーゼ治療薬
WO2011100369A2 (en) * 2010-02-09 2011-08-18 The Trustees Of Columbia University In The City Of New York Methods for altering polypeptide expression and solubility
CA2819181C (en) 2010-11-29 2020-03-10 Dako Denmark A/S Methods and systems for analyzing images of specimens processed by a programmable quantitative assay
DE102010056289A1 (de) 2010-12-24 2012-06-28 Geneart Ag Verfahren zur Herstellung von Leseraster-korrekten Fragment-Bibliotheken
EP2751729B1 (en) 2011-09-01 2020-10-21 Genome Compiler Corporation System for polynucleotide construct design, visualization and transactions to manufacture the same
WO2014153188A2 (en) 2013-03-14 2014-09-25 Life Technologies Corporation High efficiency, small volume nucleic acid synthesis
WO2013049227A2 (en) 2011-09-26 2013-04-04 Geneart Ag High efficiency, small volume nucleic acid synthesis
WO2013152220A2 (en) 2012-04-04 2013-10-10 Life Technologies Corporation Tal-effector assembly platform, customized services, kits and assays
KR102160389B1 (ko) 2013-08-05 2020-09-28 트위스트 바이오사이언스 코포레이션 드 노보 합성된 유전자 라이브러리
RU2016109938A (ru) * 2013-08-21 2017-09-26 Куревак Аг Композиция и вакцина для лечения рака предстательной железы
EP3035955B1 (en) * 2013-08-21 2019-09-11 CureVac AG Composition and vaccine for treating lung cancer
EP4043032A1 (en) * 2013-08-21 2022-08-17 CureVac AG Rabies vaccine
KR20160044566A (ko) 2013-08-21 2016-04-25 큐어백 아게 호흡기 세포융합 바이러스
EA037217B1 (ru) * 2013-08-21 2021-02-20 Куревак Аг Композиция и вакцина для лечения рака легких
BR112016001192A2 (pt) 2013-08-21 2017-08-29 Curevac Ag Vacina contra a raiva
EP3035960B1 (en) * 2013-08-21 2019-07-03 CureVac AG Respiratory syncytial virus (rsv) vaccine
EP3218508A4 (en) * 2014-11-10 2018-04-18 Modernatx, Inc. Multiparametric nucleic acid optimization
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
EP3229959B1 (en) 2014-12-09 2019-05-15 Life Technologies Corporation High efficiency, small volume nucleic acid synthesis
WO2016126882A1 (en) 2015-02-04 2016-08-11 Twist Bioscience Corporation Methods and devices for de novo oligonucleic acid assembly
US9981239B2 (en) 2015-04-21 2018-05-29 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
DK3294885T3 (da) 2015-05-08 2020-08-10 Curevac Real Estate Gmbh Fremgangsmåde til at fremstille rna
PT3303583T (pt) 2015-05-29 2020-07-07 Curevac Ag Um método para produção e purificação de rna, compreendendendo pelo menos um passo de filtração por fluxo tangencial
EP3350314A4 (en) 2015-09-18 2019-02-06 Twist Bioscience Corporation BANKS OF OLIGONUCLEIC ACID VARIANTS AND SYNTHESIS THEREOF
KR20180058772A (ko) 2015-09-22 2018-06-01 트위스트 바이오사이언스 코포레이션 핵산 합성을 위한 가요성 기판
CN115920796A (zh) 2015-12-01 2023-04-07 特韦斯特生物科学公司 功能化表面及其制备
CA3034769A1 (en) 2016-08-22 2018-03-01 Twist Bioscience Corporation De novo synthesized nucleic acid libraries
US10417457B2 (en) 2016-09-21 2019-09-17 Twist Bioscience Corporation Nucleic acid based data storage
WO2018087276A1 (en) 2016-11-10 2018-05-17 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Or10h1 modulators and uses thereof
GB2573069A (en) 2016-12-16 2019-10-23 Twist Bioscience Corp Variant libraries of the immunological synapse and synthesis thereof
CA3054303A1 (en) 2017-02-22 2018-08-30 Twist Bioscience Corporation Nucleic acid based data storage
US10894959B2 (en) 2017-03-15 2021-01-19 Twist Bioscience Corporation Variant libraries of the immunological synapse and synthesis thereof
WO2018195339A1 (en) 2017-04-19 2018-10-25 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
WO2018231864A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
AU2018284227B2 (en) 2017-06-12 2024-05-02 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
CN111566125A (zh) 2017-09-11 2020-08-21 特韦斯特生物科学公司 Gpcr结合蛋白及其合成
GB2583590A (en) 2017-10-20 2020-11-04 Twist Bioscience Corp Heated nanowells for polynucleotide synthesis
AU2019205269A1 (en) 2018-01-04 2020-07-30 Twist Bioscience Corporation DNA-based digital information storage
EP3508499A1 (en) 2018-01-08 2019-07-10 iOmx Therapeutics AG Antibodies targeting, and other modulators of, an immunoglobulin gene associated with resistance against anti-tumour immune responses, and uses thereof
US20210163922A1 (en) 2018-03-19 2021-06-03 Modernatx, Inc. Assembly and error reduction of synthetic genes from oligonucleotides
CN112639130B (zh) 2018-05-18 2024-08-09 特韦斯特生物科学公司 用于核酸杂交的多核苷酸、试剂和方法
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
JP2022522668A (ja) 2019-02-26 2022-04-20 ツイスト バイオサイエンス コーポレーション 抗体を最適化するための変異体核酸ライブラリ
WO2020176678A1 (en) 2019-02-26 2020-09-03 Twist Bioscience Corporation Variant nucleic acid libraries for glp1 receptor
CA3144644A1 (en) 2019-06-21 2020-12-24 Twist Bioscience Corporation Barcode-based nucleic acid sequence assembly
AU2020300519A1 (en) * 2019-06-30 2022-02-24 John Fraser Wright Recombinant AAV vectors with altered immunogencity and methods of making the same
EP3994171A1 (en) 2019-07-05 2022-05-11 iOmx Therapeutics AG Antibodies binding igc2 of igsf11 (vsig3) and uses thereof
AU2020356471A1 (en) 2019-09-23 2022-04-21 Twist Bioscience Corporation Variant nucleic acid libraries for CRTH2
EP3822288A1 (en) 2019-11-18 2021-05-19 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof
EP4175668A1 (en) 2020-07-06 2023-05-10 iOmx Therapeutics AG Antibodies binding igv of igsf11 (vsig3) and uses thereof
CA3186830A1 (en) * 2020-07-21 2022-01-27 Zhongdong SHI Composition and method for treating eye diseases
EP3992205A1 (en) 2020-11-03 2022-05-04 Rheinische Friedrich-Wilhelms-Universität Bonn Sars coronavirus-2 spike protein binding compounds
JP2023547507A (ja) 2020-11-03 2023-11-10 ドイチェス クレブスフォルシュンクスツェントルム スチフトゥング デス エッフェントリヒェン レヒツ 標的細胞限定的で共刺激性の二重特異性かつ２価の抗ｃｄ２８抗体
WO2022106205A1 (en) 2020-11-18 2022-05-27 Rheinische Friedrich-Wilhelms-Universität Bonn Corona virus spike protein binding compounds
US20240174768A1 (en) 2021-03-03 2024-05-30 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Bispecific antibodies enhancing cell mediated immune responses
EP4384628A2 (en) * 2021-08-11 2024-06-19 Solid Biosciences Inc. Treatment of muscular dystrophy
CN118077011A (zh) * 2022-09-30 2024-05-24 南京金斯瑞生物科技有限公司 一种降低外源核酸免疫原性的密码子优化
WO2024133940A2 (en) 2022-12-23 2024-06-27 Iomx Therapeutics Ag Cross-specific antigen binding proteins (abp) targeting leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2, combinations and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050131267A1 (en) * 1995-06-07 2005-06-16 Talmadge Karen D. System and method for delivering a therapeutic agent for bone disease
DE69838294T2 (de) * 1997-05-20 2009-08-13 Ottawa Health Research Institute, Ottawa Verfahren zur Herstellung von Nukleinsäurekonstrukten
AP1775A (en) * 1999-09-25 2007-08-28 Univ Iowa Res Found Immunostimulatory nucleic acids.
ATE319814T1 (de) 2000-03-15 2006-03-15 Prolume Ltd Luciferase, fluoreszenzproteine, für luciferase und fluoreszenzproteine kodierend nukleinsaüre und ihre verwendung in der diagnose, hoch- durchsatz screeningsverfahren
EP1156112B1 (en) * 2000-05-18 2006-03-01 Geneart GmbH Synthetic gagpol genes and their uses
US6919204B2 (en) * 2000-09-29 2005-07-19 Sangamo Biosciences, Inc. Modulation of gene expression using localization domains
DE10053781B4 (de) 2000-10-30 2008-07-03 Geneart Ag Kernexportreportersystem
JP2005500019A (ja) 2001-04-05 2005-01-06 エムエル ラボラトリーズ ピーエルシー 改良された遺伝子発現
WO2002099105A2 (en) 2001-06-05 2002-12-12 Cellectis Methods for modifying the cpg content of polynucleotides
US7605138B2 (en) * 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) * 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) * 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7316925B2 (en) * 2002-07-16 2008-01-08 Vgx Pharmaceuticals, Inc. Codon optimized synthetic plasmids
DE10260805A1 (de) * 2002-12-23 2004-07-22 Geneart Gmbh Verfahren und Vorrichtung zum Optimieren einer Nucleotidsequenz zur Expression eines Proteins
WO2005114106A1 (en) 2004-05-12 2005-12-01 Northrop Grumman Corporation System and method for aligning multiple navignation components
DK1776460T3 (da) * 2004-08-03 2010-04-12 Geneart Ag Fremgangsmåde til modulering af genekspression ved ændring af CpG-indholdet
DE102004037611B4 (de) * 2004-08-03 2013-10-02 Geneart Ag Induzierbare Genexpression
DE102007052344B3 (de) * 2007-11-02 2009-03-12 Geneart Ag Selektion kodierender Nukleinsäure-Konstrukte auf Abwesenheit von Frameshift-Mutationen
EP2970965A2 (en) * 2013-03-15 2016-01-20 Pronai Therapeutics, Inc. Dnai for the modulation of genes

Also Published As

Publication number Publication date
EP1776460A2 (de) 2007-04-25
JP4550115B2 (ja) 2010-09-22
US8859275B2 (en) 2014-10-14
ATE453716T1 (de) 2010-01-15
EP1776460B2 (de) 2013-12-25
US20090324546A1 (en) 2009-12-31
IL180786A (en) 2013-08-29
US20190270999A1 (en) 2019-09-05
US10273486B2 (en) 2019-04-30
US20150104832A1 (en) 2015-04-16
DE502005008794D1 (de) 2010-02-11
IL180786A0 (en) 2007-06-03
KR101222628B1 (ko) 2013-01-16
WO2006015789A3 (de) 2006-06-01
US20210155940A1 (en) 2021-05-27
DK1776460T3 (da) 2010-04-12
EP1776460B8 (de) 2014-02-26
HK1100089A1 (en) 2007-09-07
BRPI0513081A (pt) 2008-04-22
AU2005270430B2 (en) 2008-06-12
EP1776460B1 (de) 2009-12-30
CA2575490A1 (en) 2006-02-16
WO2006015789A2 (de) 2006-02-16
AU2005270430A1 (en) 2006-02-16
JP2008507986A (ja) 2008-03-21
KR20070041605A (ko) 2007-04-18

Similar Documents

Publication Publication Date Title
HK1100089A1 (en) Method for modulating gene expression by modifying the cpg content
WO2003014307A3 (en) Antisense modulation of apolipoprotein(a) expression
EP1569695A4 (en) ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
WO2004005460A3 (en) Antisense modulation of hmg-coa reductase expression
EP1419168A4 (en) ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
WO2002036743A3 (en) Antisense modulation of calreticulin expression
WO2003097662A8 (en) Antisense modulation of apolipoprotein b expression
EP1248794A4 (en) ANTISENSE MODULATION OF SMAD7 PROTEIN EXPRESSION
WO2003046132A3 (en) Antisense modulation of myd88 expression
WO2003014306A3 (en) Antisense modulation of cholesteryl ester transfer protein expression
WO2003053341A3 (en) Antisense modulation of ship-1 expression
WO2001083513A3 (en) Antisense modulation of inhibitor of dna binding-1 expression
WO2002095053A3 (en) Antisense modulation of src-c expression
WO2002050248A3 (en) Antisense modulation of hepsin expression
WO2004010956A3 (en) Antisense modulation of lar expression
WO2003052062A3 (en) Antisense modulation of cd36l1 expression
WO2003027229A3 (en) Antisense modulation of rip2 expression
EP1572713A4 (en) ANTISENSE MODULATION OF ACYL-COA SYNTHETASE 1 EXPRESSION
WO2004003201A3 (en) Antisense modulation of lrh1 expression
WO2003106645A3 (en) ANTISENSE MODULATION OF SMRT COREPRESSOR EXPRESSION
WO2002041836A3 (en) Antisense modulation of src-1 expression
WO2003031576A3 (en) Antisense modulation of inhibitor-kappa b kinase-gamma expression
WO2003050247A3 (en) Antisense modulation of mhc class ii transactivator expression
WO2004015126A3 (en) Antisense modulation of edg1 expression
WO2003099204A3 (en) Antisense modulation of inhibitor-kappa b kinase-beta expression

Legal Events

Date Code Title Description
FA Abandonment or withdrawal